Effect of Losartan and Fish Oil on Plasma IL-6 and Mobility in Older Persons. The ENRGISE Pilot Randomized Clinical Trial.
J Gerontol A Biol Sci Med Sci
; 74(10): 1612-1619, 2019 09 15.
Article
em En
| MEDLINE
| ID: mdl-30541065
ABSTRACT
BACKGROUND:
Low-grade chronic inflammation, characterized by elevations in plasma Interleukin-6 (IL-6), is an independent risk factor of impaired mobility in older persons. Angiotensin receptor blockers and omega-3 polyunsaturated fatty acids (ω-3) may reduce IL-6 and may potentially improve physical function. To assess the main effects of the angiotensin receptor blocker losartan and ω-3 as fish oil on IL-6 and 400 m walking speed, we conducted the ENRGISE Pilot multicenter randomized clinical trial.METHODS:
The ENRGISE Pilot enrolled participants between April 2016 and June 2017, who participated for 12 months. Participants were aged ≥70 years with mobility impairment, had IL-6 between 2.5 and 30 pg/mL, and were able to walk 400 m at baseline. Participants were randomized in three strata 2 × 2 factorial to (i) losartan 50-100 mg/d or placebo (n = 43), (ii) fish oil 1,400-2,800 mg/d or placebo (n = 180), and (iii) with both (n = 66).RESULTS:
Two hundred eighty-nine participants were randomized (mean age 78.3 years, 47.4% women, 17.0% black). There was no effect of losartan (difference of means = -0.065 ± 0.116 [SE], 95% confidence interval [CI] -0.293-0.163, p = .58) or fish oil (-0.020 ± 0.077, 95% CI -0.171-0.132, p = .80) on the log of IL-6. Similarly, there was no effect of losartan (-0.025 ± 0.026, 95% CI -0.076-0.026, p = .34) or fish oil (0.010 ± 0.017, 95% CI -0.025-0.044, p = .58) on walking speed (m/s).CONCLUSIONS:
These results do not support the use of these interventions to prevent mobility loss in older adults at risk of disability with low-grade chronic inflammation. REGISTRATION Clinicaltrials.gov NCT02676466.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ácidos Graxos Ômega-3
/
Interleucina-6
/
Losartan
/
Bloqueadores do Receptor Tipo 1 de Angiotensina II
/
Limitação da Mobilidade
/
Velocidade de Caminhada
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article